RU2017125735A - Химерные антигенные рецепторы против карбоангидразы ix и способы их применения - Google Patents

Химерные антигенные рецепторы против карбоангидразы ix и способы их применения Download PDF

Info

Publication number
RU2017125735A
RU2017125735A RU2017125735A RU2017125735A RU2017125735A RU 2017125735 A RU2017125735 A RU 2017125735A RU 2017125735 A RU2017125735 A RU 2017125735A RU 2017125735 A RU2017125735 A RU 2017125735A RU 2017125735 A RU2017125735 A RU 2017125735A
Authority
RU
Russia
Prior art keywords
amino acid
seq
acid sequence
car
cdr2
Prior art date
Application number
RU2017125735A
Other languages
English (en)
Russian (ru)
Inventor
Уэйн А. МАРАСКО
Original Assignee
Дана-Фарбер Кэнсер Инститьют, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дана-Фарбер Кэнсер Инститьют, Инк. filed Critical Дана-Фарбер Кэнсер Инститьют, Инк.
Publication of RU2017125735A publication Critical patent/RU2017125735A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01001—Carbonate dehydratase (4.2.1.1), i.e. carbonic anhydrase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2017125735A 2014-12-19 2015-12-21 Химерные антигенные рецепторы против карбоангидразы ix и способы их применения RU2017125735A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094596P 2014-12-19 2014-12-19
US62/094,596 2014-12-19
PCT/US2015/067178 WO2016100980A1 (en) 2014-12-19 2015-12-21 Carbonic anhydrase ix specific chimeric antigen receptors and methods of use thereof

Publications (1)

Publication Number Publication Date
RU2017125735A true RU2017125735A (ru) 2019-01-22

Family

ID=55273519

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017125735A RU2017125735A (ru) 2014-12-19 2015-12-21 Химерные антигенные рецепторы против карбоангидразы ix и способы их применения

Country Status (11)

Country Link
US (3) US10870705B2 (enExample)
EP (1) EP3233901A1 (enExample)
JP (1) JP2018500337A (enExample)
KR (1) KR20170093248A (enExample)
CN (1) CN108064251A (enExample)
AU (1) AU2015364240A1 (enExample)
BR (1) BR112017013177A2 (enExample)
CA (1) CA2968555A1 (enExample)
IL (1) IL252366A0 (enExample)
RU (1) RU2017125735A (enExample)
WO (1) WO2016100980A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017125531A (ru) * 2014-12-19 2019-01-21 Дана-Фарбер Кэнсер Инститьют, Инк. Химерные антигенные рецепторы и способы их применения
WO2018119198A1 (en) * 2016-12-22 2018-06-28 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
JP2021512875A (ja) * 2018-02-02 2021-05-20 カースゲン セラピューティクス カンパニー リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． 細胞免疫療法の組み合わせ
JP7649239B2 (ja) * 2018-11-30 2025-03-19 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド キメラ抗原受容体ファクトリおよびその使用方法
CN109705225B (zh) * 2019-01-21 2022-02-22 徐州医科大学 一种抗人caix抗原的嵌合抗原受体及其应用
WO2020226612A1 (en) * 2019-05-06 2020-11-12 Navi Bio-Therapeutics, Llc Anti-carbonic anhydrase ix antibody
TWI869344B (zh) * 2019-05-06 2025-01-11 納維再生科技股份有限公司 抗-碳酸酐酶ix抗體
CN112552408B (zh) * 2019-09-10 2022-09-20 普米斯生物技术(珠海)有限公司 靶向caix抗原的纳米抗体及其应用
WO2021055973A2 (en) * 2019-09-20 2021-03-25 Navi Bio-Therapeutics, Inc. Personalized cancer immunotherapy
CN113045665B (zh) * 2021-03-22 2022-05-13 徐州医科大学 一种hvem共刺激信号驱动的caix-car-t细胞及其制备方法和应用
CA3217029A1 (en) 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
EP4321526A4 (en) 2022-02-11 2026-04-15 C Biomex Co Ltd Peptide ligand targeting carbonic anhydrase IX, peptide construction comprising it, and associated uses
CN116102662A (zh) * 2022-10-10 2023-05-12 武汉波睿达生物科技有限公司 一种靶向ca9的融合嵌合抗原受体、重组表达载体及其应用
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向ｐｓｍａ及ｃａ９之系統
WO2025064539A1 (en) 2023-09-19 2025-03-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Herv-e antibodies and methods of their use
WO2026096443A1 (en) * 2024-10-30 2026-05-07 Link Cell Therapies Inc. Synthetic receptors for control and specific treatment of renal cell carcinoma with car t cells
WO2026117666A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Bispecific antibodies for treating cancer
WO2026117664A1 (en) * 2024-11-26 2026-06-04 Dana-Farber Cancer Institute, Inc. Engineered cells and uses thereof for treating cancer
WO2026148120A2 (en) 2024-12-31 2026-07-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Car with dual-variable domain and enhanced tcr-signaling targeting ct-rcc-1 peptide and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2572277A1 (en) 2004-06-30 2006-01-12 Cordis Corporation Intraluminal medical device having asymetrical members and method for optimization
EP1979379B1 (en) * 2005-12-02 2013-09-18 Dana-Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
FR2933058B1 (fr) 2008-06-30 2010-08-27 Zf Systemes De Direction Nacam Sas Dispositif d'assistance au verrouillage d'une colonne de direction
DE102008030837A1 (de) 2008-06-30 2010-01-14 Siemens Aktiengesellschaft Elektrochrome Formulierung, Herstellungsverfahren dazu und elektrochromes organisches Bauelement
EP2934532B1 (en) * 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3789487A1 (en) 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
FR3023477B1 (fr) 2014-07-10 2017-11-24 Oreal Utilisation cosmetique de l'acide spiculisporique comme actif deodorant

Also Published As

Publication number Publication date
US20250011462A1 (en) 2025-01-09
EP3233901A1 (en) 2017-10-25
US20210221906A1 (en) 2021-07-22
IL252366A0 (en) 2017-07-31
US20180030147A1 (en) 2018-02-01
KR20170093248A (ko) 2017-08-14
WO2016100980A1 (en) 2016-06-23
CN108064251A (zh) 2018-05-22
CA2968555A1 (en) 2016-06-23
BR112017013177A2 (pt) 2018-05-15
AU2015364240A1 (en) 2017-06-08
US12024567B2 (en) 2024-07-02
US10870705B2 (en) 2020-12-22
JP2018500337A (ja) 2018-01-11

Similar Documents

Publication Publication Date Title
JP2018500337A5 (enExample)
RU2018111462A (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
FI4063397T3 (fi) Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
FI3703750T3 (fi) B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja
CN107880128B (zh) 一种抗cd19的全人源抗体或抗体片段及其方法和应用
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
RU2018135247A (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК
JP2018504094A5 (enExample)
JP2018506981A5 (enExample)
RU2022102250A (ru) Клетка
JP2018520657A5 (enExample)
IL273402B2 (en) Antibodies against human leukocyte antigens type A2 and methods of using them
IL265541B1 (en) Bispecific antibodies and compositions comprising thereof for treating cancer
JOP20180042A1 (ar) نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
IL320860A (en) Chimeric antigen receptors and methods of using them
JP2019513370A5 (enExample)
JP2019500891A5 (enExample)
JP2019525738A5 (enExample)
RU2018105963A (ru) Антитело против глипикана-3 и его применение
RU2016138422A (ru) Химерный антигенный рецептор
RU2018146533A (ru) Антитела к cd40 и пути их применения
RU2018134771A (ru) Клетки, экспрессирующие множество молекул химерных антигенных рецепторов (car), и их применение
RU2017102769A (ru) EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА
FI3708579T3 (fi) Claudin-6-spesifiset immuunoreseptorit ja t-soluepitoopit
RU2016143381A (ru) Способ и композиции для клеточной иммунотерапии

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20200720